INTRODUCTION
============

*Clostridium difficile*, a Gram-positive spore-forming bacillus, is the most common identifiable etiologic agent of antibiotic-associated diarrhea ([@R13], [@R18]). Initially described as a member of the commensal microbiota of neonates, *C. difficile* was identified as a causal agent of antibiotic-associated diarrhea in the 1970s ([@R3], [@R11]). The clinical presentation of *C. difficile*-associated disease (CDAD) can range from asymptomatic carriage in the gastrointestinal tract, mild diarrhea, and potentially fatal pseudomembranous colitis ([@R13], [@R18]). Symptoms occur secondary to the production of two exotoxins, toxin A and toxin B, which disrupt the integrity of the colonic mucosa ([@R24]).

Alarming changes in the epidemiology of CDAD, including an increase in both the incidence and severity of the disease, have highlighted concerns about patterns of *C. difficile* infection ([@R17], [@R18], [@R19], [@R21]). Analysis of U.S. hospital discharge data revealed that the national rates of CDAD doubled from 2000 to 2003 ([@R17]). In 2004, the Centers for Disease Control and Prevention reported that the mortality rate related to CDAD increased from 5.7 deaths per million individuals in 1999 to 23.7 deaths per million individuals ([@R21]). In addition to the profound morbidity and mortality, CDAD is also generating a substantial economic burden, with estimates ranging from \$1.3 million to more than \$3 billion annually ([@R8], [@R16], [@R20]). Due to the formidable impact of CDAD on the U.S. health care system, rapid and accurate diagnosis is essential for the timely enactment of infection control and treatment measures.

The changing epidemiology of *C. difficile* infections in the pediatric population is a serious concern. While benign neonatal colonization with toxigenic *C. difficile* is a well-documented phenomenon, recent studies have suggested an increased incidence of CDAD in children ([@R2], [@R14], [@R22], [@R25]). A large study encompassing data collected from 22 children's hospitals in the United States reported an increased prevalence of CDAD in children, including infants (increased by 53% from 2001 to 2006, with 26% of patients with CDAD ≤1 year of age) ([@R14]). Utilizing CDAD data from the Agency for Healthcare and Research Quality, a similar study noted that the highest number of CDAD hospitalizations occurred in patients ≤1 year of age ([@R25]).

Initial strategies to detect *C. difficile* consisted of anaerobic stool sample culture, usually with cycloserine-cefoxitin-fructose agar (CCFA) or a similar medium with or without a pretreatment alcohol shock step ([@R7]). Although this modality was quite sensitive and specific for detecting *C. difficile*, it took up to 5 days to confirm a negative culture and it did not discriminate between toxigenic and nontoxigenic isolates without further testing strategies. Furthermore, colonies with indeterminate colony characteristics were tested with L-proline-aminopeptidase (PRO Disc) or other biochemical tests to ensure the accurate identification of *C. difficile* ([@R9], [@R10]). The development of the cell culture cytotoxicity assay circumvented stool sample culture by observing cytopathic effects of toxin B directly on cultured cells ([@R4], [@R6]). The cell culture cytotoxicity assay requires a neutralization step for specificity and maintenance of toxin-susceptible mammalian cell lines, and it takes 48 to 72 h to perform the assay ([@R1], [@R5]). Rapid antigen detection assays, consisting of common antigen testing (glutamate dehydrogenase) and toxin immunoassays, have largely replaced culture and the cytotoxic assay; however, neither type has the desired sensitivity or specificity to reliably confirm or rule out CDAD without the need for either serial testing or subsequent testing modalities. Therefore, real-time PCR is being investigated as the preferred diagnostic modality due to its rapid turnaround time and track record of superior sensitivity and specificity.

Toxigenic strains of *C. difficile* contain a 19.6-kb pathogenicity locus (PaLoc) that includes five contiguous chromosomal genes responsible for the development of CDAD---*tcdABCDE* ([@R24]). *tcdA* and *tcdB*encode exotoxins A (enterotoxin) and B (cytotoxin), respectively; *tcdC* and *tcdD*encode negative and positive regulators, respectively, that control the level of toxin production; and *tcdE* is purported to encode a holin-like protein thought to facilitate toxin release from the bacterial cell wall ([@R24]). Because toxins A and/or B are implicated in CDAD and genetic diversity of the PaLoc has been reported ([@R23]), we developed and clinically validated one hydrolysis probe real-time PCR assays targeting the *tcdB* genes ([@R12], [@R15], [@R24]). While the molecular methods utilized by this assay were not novel, the application of molecular testing for *C. difficile* infection is unique when the stool sample could be tested directly without nuclear acid extraction. This will greatly facilitate quick testing of c. difficile in clinical setting.

MATERIALS AND METHOD
====================

C. difficile Strains: The following strains were used for LoD study: C. difficile ATCC 43255 (ZeptoMetrix), C. difficile NAP1A (ZeptoMetrix).

Extraction, Real-time PCR Amplification and Detection: Lab developed C. difficile Direct Kit contains all reagents for on-board extraction and real-time PCR amplification.

Fifty μL of C. difficile Direct reaction mix was loaded into the reaction port and 50 μL of sample was directly loaded into the sample port on the Amplification cell. All testing was performed using real time PCR. Assay time is about 60 minutes.

Limit of Detection (LoD): The LoD for each C. difficile stock was determined as the lowest concentration with ≥95% detection in negative stool matrix.

Reproducibility: Thirty-six replicates of the following contrived panel in negative stool matrix were tested: C. difficile Low Positive (ATCC 43255), C. difficile Medium Positive (ATCC 43255), C. difficile Low Positive (NAP1A), C. difficile Medium Positive (NAP1A). Low Positive was defined as 1X LoD; medium positive was defined as 3X LoD.

Positive and Negative Agreement: A panel of 150 de-identified clinical specimens was evaluated using the Lab developed C. difficile Direct assay. Lab developed test results were compared to Cepheid Xpert C. difficile and enriched culture results.

Cross-Reactivity: The cross-reactivity panel of 126 different organisms consisted of industry equivalent 106 CFU/mL of bacteria or 105 TCID50/mL of virus in negative stool matrix.

Inhibition/interference: The interference panel was contrived with the ATCC 43255 or NAP1A strain at 4-fold the LoD concentration. Each substance was spiked into the C. difficile contrived stool samples and tested using Lab developed C. difficile Direct.

RESULTS
=======

Limit of Detection: C. difficile ATCC 43255 LoD was 0.5 CFU/mL. C. difficile NAP1A strain LoD was 1.6 CFU/mL in stool matrix (Table [1](#T1){ref-type="table"}).

###### 

*C. difficile* Limit of Detection

  Bacterial Strain   (LoD) Concentration   Detection Rate   Average Ct   Maximum Ct   Minimum Ct
  ------------------ --------------------- ---------------- ------------ ------------ ------------
                                                                                      
  ATCC 43255         0.5 CFU/mL            95% (19/20)      39.1         41           38.5
  NAP1A              1.3 CFU/mL            100% (20/20)     39.1         42.0         38.4

C. difficile Reproducibility: For ATCC 43255 and NAP1A medium- and low-contrived panels, C. difficile strains were detected in 100% of replicates. Standard deviations were \<0.99. Percent coefficients of variation were \<3.3 (Table [2](#T2){ref-type="table"}).

###### 

Lab developed C. difficile Direct Quantitative Reproducibility

                  Between Instrument   Between Operator   Between Run   Within Run   Total                                            
  --------------- -------------------- ------------------ ------------- ------------ ------- --- --- ------ ----- ------ ----- ------ -----
                                                                                                                                      
  C. diff (FAM)   Low Pos 43255        36                 38.7          0            0       0   0   0      0     0.87   2.6   0.94   2.7
                  Low Pos NAP1A        36                 38.8          0            0       0   0   0.7    1     0.76   1.8   0.74   1.9
                  Med Pos 43255        36                 38            0.31         0.9     0   0   0      0     0.53   2     0.83   2.3
                  Med Pos NAP1A        36                 37.2          0.16         0.2     0   0   0      0     0.58   1.7   0.52   1.2
                  Pos Control          36                 31.2          0.27         0.5     0   0   0.1    0.3   0.37   1.6   0.38   1.6
  IC (Q670)       Low Pos 43255        36                 29.9          0            0       0   0   0      0     0.87   3.1   0.99   3.1
                  Low Pos NAP1A        36                 29.8          0.28         0.9     0   0   0      0     0.74   2.3   0.76   2.8
                  Med Pos 43255        36                 29.6          0.26         0.5     0   0   0      0     0.62   2.3   0.69   2.4
                  Med Pos NAP1A        36                 29.9          0.35         1.5     0   0   0      0     0.6    2.4   0.75   2.6
                  Negative             36                 30.1          0.12         0.4     0   0   0.22   0.7   0.79   2.8   0.81   2.5
                  Pos Control          36                 30.8          0.33         1       0   0   0      0     0.7    2.2   0.76   2.9

C. difficile Positive and Negative Agreement: Results from Lab developed C. difficile Direct and Cepheid Xpert C. difficile were in agreement for 95% of positive specimens and 97% of negative specimens (Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}).

###### 

Lab developed C. difficile Direct Positive and Negative Agreement

                                         Lab developed *C. difficile* Direct vs Cepheid Xpert *C. difficile* (n=150)   Lab developed *C. difficile* Direct vs Enriched Culture (n=110)
  -------------------------------------- ----------------------------------------------------------------------------- -----------------------------------------------------------------
                                                                                                                       
  **Positive Agreement (Sensitivity)**   95%                                                                           93%
  **Negative Agreement (Specificity)**   97%                                                                           94%

###### 

Lab developed C. difficile Direct Agreement with Cepheid Xpert C. difficile

                                            Cepheid Xpert *C. difficile*   Total         
  ----------------------------------------- ------------------------------ ------- ----- -----
                                                                                         
  **Lab developed *C. difficile* Direct**   **Positive**                   32      3     35
                                            **Negative**                   2       113   115
                                            **Total**                      34      116   150

Results from Lab developed C. difficile Direct and enriched culture were in agreement for 93% of positive specimens and 94% of negative specimens (Tables [3](#T3){ref-type="table"} and [5](#T5){ref-type="table"}).

###### 

Lab developed C. difficile Direct Agreement with Enriched Toxigenic Culture

                                            *C. difficile* Enriched Toxigenic Culture   Total         
  ----------------------------------------- ------------------------------------------- ------- ----- -----
                                                                                                      
  **Lab developed *C. difficile* Direct**   **Positive**                                41      6     47
                                            **Negative**                                3       100   103
                                            **Total**                                   44      106   150

Cross-Reactivity: No cross-reactivity was detected with the 126 pathogens tested (subset of representative strains listed in Table [6](#T6){ref-type="table"}).

###### 

C. difficile Cross-Reactivity Pathogens Tested in Stool Matrix (Representative Strains)

  -------------------------------------- -------------------------- -------------------------------------------------
  Abiotrophia defectivear                Candida catenulate         Clostridium septicum
  Acinetobacter baumannii                Clostridium bifermentans   Ciostridium tetani
  Acinetobacter Iwoffii                  Clostridium bolteae        Clostridium difficile (non-toxigenic ATCC43593)
  Aeromonas hydrophila                   Clostridium butyricum      Desulfovibrio piger
  Alcaligenes faecalis subsp. Faecalis   Clostridium chauvoei       Edwardsiella tarda
  Bifidobacterium longum                 Clostridium fallax         Eggerthellalenta
  Campylobacter coli                     Clostridium ramosurn       Enterobacter aerogenes
  Campylobacter jejuni sub sp .jejuni    Clostridium scindens       Enterobacter cloacae
  Candida albicans                                                   
  -------------------------------------- -------------------------- -------------------------------------------------

Substance Interference: No interference was detected with the substances tested (Table [7](#T7){ref-type="table"}).

###### 

Interferents Tested in Stool Matrix

  Substance                          Active Ingredient                         Starting Interferent Concentration   Final Sample Concentration[a](#T7FN1){ref-type="table-fn"}
  ---------------------------------- ----------------------------------------- ------------------------------------ ------------------------------------------------------------
                                                                                                                    
  Antacid and anti-gas generic       Aluminum hydroxide, magnesium hydroxide   1 mg/mL                              0.1 mg/mL
  Milk of Magnesia (liquid)          Magnesium hydroxide                       2 mg/mL                              0.2 mg/mL
  Antacid generic                    Calcium carbonate                         1 mg/mL                              0.1 mg/mL
  Metronidazole                      Metronidazole                             140 mg/mL                            14 mg/mL
  Vancomycin                         Vancomycin                                14 mg/mL                             1.4 mg/mL
  Stearic acid                       Stearic acid                              40 mg/mL                             4 mg/mL
  Palmitic acid                      Palmitic acid                             20 mg/mL                             2 mg/mL
  Barium sulfate                     Barium sulfate                            50 mg/mL                             5 mg/mL
  Loperamide hydrochloride generic   Loperamide                                0.05 mg/mL                           0.005 mg/mL
  Pepto-Bismol (liquid)              Bismuth subsalicylate                     1.75 mg/mL                           0.175 mg/mL
  Preparation H                      Phenylephrine                             20% (w/v)                            2% (w/v)
  Trojan with nonoxynol-9            Nonoxynol-9                               14 mg/mL                             1.4 mg/mL
  1% hydrocortisone cream generic    Hydrocortisone                            20% (w/v)                            2% (w/v)
  Fleet                              Mineral oil                               20% (w/v)                            2% (v/v)
  Laxative generic                   Sennosides                                1 mg/mL                              0.1 mg/mL
  Moist towelettes generic           Benzalkonium chloride                     100% (v/v)                           10% (v/v)
  KY Jelly                           Glycerin                                  20% (w/v)                            2% (w/v)
  Nystatin (6,000 USP units/mg)      Nystatin                                  100,000 USP/mL                       10,000 USP units/mL
  Naproxen sodium generic            Naproxen                                  140 mg/mL                            14 mg/mL
  Mucin                              Mucin                                     30 mg/mL                             3 mg/mL
  Whole blood (donor: RH)            Whole blood                               50% (v/v)                            5% (v/v)
  TE (spiked baseline)               None                                      N/A                                  N/A

For each substance, 100 μL of interferent at starting interferent con-centration was added to 900 μL of stool matrix.

CONCLUSION
==========

Lab developed C. difficile Direct can provide an option for simplified C. difficile testing on the real time PCR. This test was also comparable to both Xpert C. difficile and enriched toxigenic culture for identifying C. difficile.
